PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: England
The UK's New "Revolutionary" Medicines Optimization Plan
By Leela Barham.
The UK’s Royal Pharmaceutical Society has joined forces with a number of other organizations, including the Association of the British Pharmaceutical Industry (ABPI), to issue new guidance on medicines optimization. Sir Bruce Keogh, Medical Director of NHS England, says it could be revolutionary.
Posted in Europe, Global, Guest Blog, Op-Ed Also tagged ABPI, medicines optimization, NHS, NICE, Royal Pharmaceutical Society, UK Leave a comment
England's Cancer Drug Fund: An Acid Test for Value Based Pricing
By Leela Barham.
England’s Cancer Drugs Fund (CDF) could be in its final financial year, after running in full since April 2011. The fund covers the cost of cancer treatments either when NICE has said ‘no’, or hasn’t yet come to a view. Companies can’t circumvent NICE though; if a company was invited to submit to [...]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing Also tagged cancer drug fund, NHS, NICE, UK, value-based pricing Leave a comment
Naughty Localities Need to Obey NICE, or Else!
Like governors in the US vowing to block Medicaid expansion in their home states, local primary care trusts (PCTs) in the UK don’t always follow national guidelines on drug access due to budgetary concerns. But that may change in 2013; according to comments made by Minister David Willetts last month, NHS could face monetary penalties [...]
Posted in Agency Insight, Global, Legal, Market Access, Regulatory, Strategy, healthcare, pricing Also tagged Department of Health, Minister David Willetts, NHS, PCTs, Primary Care Trusts, public policy, Sir Michael Rawlins, UK Leave a comment
England's Latest Innovation Scorecard: A Patchy Picture